BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 2 August 2025

Organ-in-Cube: Next Generation Bionic Organ for Precision Medicine

Jiang Liu

Research Assistant Professor at Oncoimmunostics Limited

Hong Kong, China (Hong Kong)

About

Oncoimmunostics focuses on precision diagnostics and therapeutics by applying 3D bioprinting technology and AI to construct the patient-derived biomimetic disease microenvironment "Organ-in-Cube", which is the world’s first 3D-bioprinted pathologically bionic New Approach Methodology. “Organ-in-Cube” provides a fast, reliable pathway to personalized treatment selection while enabling standardized, high-throughput drug efficacy and toxicity evaluation. The product can also be used for preclinical drug efficacy evaluation, safety assessment, and pharmacokinetics for new drugs, which serves as a viable alternative to animal models and accelerates preclinical testing with accurate human-relevant data. “Organ-in-Cube” has a short manufacturing time, high biomimicry, high consistency and is superior to current organoid models and animal models.

Project Location

  • China (Hong Kong)

Project Website

oncoimmunostics.com

Project Format

  • Public-Private Partnership Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Operations

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Total Project Value

  • 10,000,001 to 25,000,000 USD

Investment Capital Required

  • 5,000,001 to 7,500,000 USD

Interested Format of Cooperation

  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Private Equity & Venture Capital
  • Risk Management (Financial Services)

Professional Services

  • Business Valuation
  • Consultancy
  • Financial Advisory
  • IP Related
  • Risk Management

Attached files

Organisation

Oncoimmunostics Limited

Hong Kong, China (Hong Kong)

Similar opportunities